|
Comparison of Response in HBsAg-positive patients treated with or without rituximab |
|||
| Use of rituximab (N = 27) (33.3%) |
No rituximab (N = 54) (66.7%) |
p-value |
|
|
|
|||
| Complete response |
19 (70.4) |
24(44.4) |
0.16 |
| Partial response |
6 (22.2) |
25(46.3) |
|
| Stable disease |
1(3.7) |
3(5.6) |
|
| Progressive disease |
1(3.7) |
2(3.7) |
|
Wang et al. BMC Cancer 2008 8:115 doi:10.1186/1471-2407-8-115 |
|||